0000000000424529

AUTHOR

Yves-marie Pers

0000-0001-5927-3773

showing 2 related works from this author

Development and Validation of a Self-Administered Multidimensional Prognostic Index to Predict Negative Health Outcomes in Community-Dwelling Persons

2019

The multidimensional prognostic index (MPI) is a comprehensive geriatric assessment (CGA)-based tool that accurately predicts negative health outcomes in older subjects with different diseases and settings. To calculate the MPI several validated tools are assessed by health care professionals according to the CGA, whereas self-reported information by the patients is not available, but it could be of importance for the early identification of frailty. We aimed to develop and validate a self-administered MPI (SELFY-MPI) in community-dwelling subjects. For this reason, we enrolled 167 subjects (mean age = 67.3, range = 20-88 years, 51% = men). All subjects underwent a CGA-based assessment to c…

Male0301 basic medicineGerontologySelf-assessmentendocrine systemAgingIndex (economics)Self AdministrationHealth outcomes03 medical and health sciences0302 clinical medicineall-cause mortality risk factor multidimensional prognostic index self-assessment comprehensive geriatric assessment socioeconomic analysissocioeconomic analysisActivities of Daily LivingHumansMedicineRisk factorAgedAged 80 and overbusiness.industryGeriatric assessmentOriginal ArticlesMiddle Agedcomprehensive geriatric assessmentPrognosisself-assessmentmultidimensional prognostic index030104 developmental biologyrisk factorSelf-Administeredall-cause mortalityFemaleIndependent LivingPublic HealthGeriatrics and Gerontologybusiness030217 neurology & neurosurgeryAll cause mortality
researchProduct

Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice

2015

International audience; Objective. The aim of this study was to evaluate the impact of introducing tocilizumab (TCZ) as co-therapy with CS in patients with RA.Methods. This study was an open, observational, retrospective multicentre study. RA patients treated with oral CS for >3 months who started treatment with TCZ between December 2009 and June 2011 in five centres were included. Variables included demographic data, disease history, co-treatments, disease activity and dose of CS at inclusion and at weeks 4, 8, 12 and 24. The evolution of disease activity and of the dose of CS (analysis of variance with repeated measures) were analysed, searching for factors correlated with changes in the …

Malerheumatoid arthritisGastroenterologycorticosteroidsArthritis Rheumatoidchemistry.chemical_compoundPrednisoneAdrenal Cortex HormonesPharmacology (medical)risksystemic glucocorticoid therapytreatmentfactor-alpha inhibitorsMiddle Aged3. Good healthClinical PracticeTreatment Outcome[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemRheumatoid arthritisAntirheumatic AgentsCorticosteroidDrug Therapy CombinationFemaleAnalysis of variancemanagementmedicine.drugAdultmedicine.medical_specialtymedicine.drug_classAntibodies Monoclonal Humanizeddiseases[ SDV.MHEP.RSOA ] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemtocilizumabTocilizumabRheumatology[SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/MedicationInternal medicinemedicineHumansIn patientbiologicsGlucocorticoidsAgedRetrospective Studiesbusiness.industry[ SDV.SP.MED ] Life Sciences [q-bio]/Pharmaceutical sciences/MedicationRepeated measures designeular recommendationsmedicine.diseaseEndocrinologychemistryPrednisonebusiness
researchProduct